

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>A61K 9/72, B65D 25/08, A61K 31/135</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/17754</b> <b>(43) International Publication Date:</b> <b>15 April 1999 (15.04.99)</b>
<b>(21) International Application Number:</b> <b>PCT/US98/21115</b> <b>(22) International Filing Date:</b> <b>7 October 1998 (07.10.98)</b>  <b>(30) Priority Data:</b> <b>60/061,363</b> <b>8 October 1997 (08.10.97)</b> <b>US</b>		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW. ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
<b>(71) Applicant:</b> SEPRACOR INC. [US/US]; 111 Locke Drive, Marlborough, MA 01752 (US).  <b>(72) Inventors:</b> REDMON, Martin, P.; 300 Stearns Road, Marlborough, MA 01752 (US). WEST, Joseph, A.; 19 Fieldstone Drive, Mansfield, MA 02048 (US).  <b>(74) Agents:</b> HANSEN, Philip, E. et al.; Heslin & Rothenberg, P.C., 5 Columbia Circle, Albany, NY 12203 (US).		<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

**(54) Title:** DOSAGE FORM FOR AEROSOL ADMINISTRATION

**(57) Abstract**

A method for preparing aerosols of water-sensitive medicaments and a pharmaceutical kit for aerosol administration are disclosed. The kit includes (a) a solid state open matrix network of a medicament in a first container, and (b) an aqueous vehicle in a second container. The first and second containers may be separate or they may be chambers within a single housing. The solid state network may be a unit dose of medicament, and the quantity of aqueous vehicle will then be that quantity needed to deliver one unit dose by aerosol; alternatively, the solid state network may contain a plurality of unit doses of medicament, in which case the quantity of aqueous vehicle will be that quantity needed to deliver the number of unit doses in the network. The kit may also include a metered dose nebulizer. A preferred medicament for use in the method is formoterol.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

## DOSAGE FORM FOR AEROSOL ADMINISTRATION

Field of the Invention

This invention relates to the delivery of therapeutic liquids to the respiratory system.

5

Background of the Invention

Aerosol formulations are employed in respiratory therapy for the topical administration of medication to the mucosal linings of the tracheobronchial tree. The term aerosol describes a nebulized solution consisting of very fine particles carried by a gas (usually air) to the site of therapeutic application. When the site 10 of application is the alveoli and small bronchioles, the medicament must be dispersed as droplets of roughly 5 micron diameter. When the target is the nasal and pharyngeal region, larger droplets are appropriate. Conditions susceptible to treatment with aerosols include bronchospasms, loss of compliance, mucosal edema, pulmonary infections and the like.

15

Solutions of medicament in buffered saline and similar vehicles are commonly employed to generate an aerosol in a nebulizer. Within the container of a conventional air-driven nebulizer is a small unit that produces aerosolized droplets inside the flask. The walls of the flask act as a baffle removing large droplets from the mist. The large droplets run down the wall and drop back into 20 the reservoir, leaving a mist of small droplets that can penetrate into the lung. A current of air or oxygen carries the fine mist through the large outlet tube of the nebulizer. Simple nebulizers operate on Bernoulli's principle and employ a stream of air or oxygen to generate the spray particles. More complex nebulizers employ ultrasound to create the spray particles. Both types are well known in the

art and are described in standard textbooks of pharmacy such as Sprowls' American Pharmacy and Remington's The Science and Practice of Pharmacy. Other devices for generating aerosols employ compressed gases, usually hydrofluorocarbons and chlorofluorocarbons, which are mixed with the 5 medicament and any necessary excipients in a pressurized container; these devices are likewise described in standard textbooks such as Sprowls and Remington. Because all nebulizers require a fluid medium for the development of the aerosol spray, and because the spray is to be inspired directly into the lung, water is the only vehicle that can reasonably be employed. A problem thus arises 10 when the medicament is itself not sufficiently stable in an aqueous environment to provide a practical shelf life for the aqueous formulation.

Various methods have been tried to circumvent this problem. It is known in the art to prepare and maintain the aqueous solution or suspension at a reduced temperature. This approach has two drawbacks: first, storage becomes expensive 15 and bothersome; and second, the degradative processes are slowed, but they are not stopped.

An alternative to refrigerating a solution or suspension that has already been prepared is to make up the medicament solution immediately before use. However, the accurate and sterile transfer of the medicament into the carrier is 20 generally only practical when the medicament is provided as a solution in another (non-aqueous) solvent. The formulations chemist is then faced with the problem of devising not just one, but two stable, compatible formulations.

Therefore, it would be highly desirable to have a system for generating 25 water-based aerosols from water-sensitive medicaments without the need for refrigeration. This need is satisfied, the limitations of the prior art overcome, and other benefits realized in accordance with the principles of the present invention.

Summary of the Invention

In one aspect, the invention relates to a pharmaceutical kit for aerosol administration. In one embodiment the kit comprises (a) a solid state open matrix network of a medicament and a pharmaceutically acceptable water soluble or water-dispersible carrier material contained within a first substantially water-impermeable container; and (b) a sufficient quantity of an aqueous vehicle to dissolve the matrix network within fifteen seconds contained within a second substantially water-impermeable container. The first and second containers may be separate or they may be chambers within a single housing. The solid state network may be a unit dose of medicament, and the quantity of aqueous vehicle will then be that quantity needed to deliver one unit dose by nebulization; alternatively, the solid state network may contain a plurality of unit doses of medicament, in which case the quantity of aqueous vehicle will be that quantity needed to deliver the number of unit doses in the network. The kit may also include a metered dose nebulizer.

In another embodiment of the kit aspect, the kit may comprise a solid state open matrix network of a medicament and a pharmaceutically acceptable water soluble or water-dispersible carrier material contained within a nebulizer reservoir and enclosed by a substantially water-impermeable seal. The seal will be penetrated or removed by the patient prior to using the nebulizer, and an aqueous vehicle will be added. As before, the solid state network may contain one or a plurality of unit doses of the medicament.

In another aspect, the invention relates to a method for preparing a formulation for nebulization. The method comprises: (a) providing a solid state open matrix network of a medicament and a pharmaceutically acceptable water soluble or water-dispersible carrier material; and (b) combining the matrix network with a sufficient quantity of an aqueous vehicle to dissolve the matrix network within fifteen seconds. In a closely related method aspect, the aqueous

solution from (b) is converted to an aerosol by nebulization. The solution may be converted to an aerosol by a conventional nebulizer or by a metered dose nebulizer.

In another aspect, the invention relates to a method for providing a water-sensitive medicament for administration as a nebulized aqueous aerosol. The method comprises: (a) dissolving or suspending a water-sensitive medicament and a pharmaceutically acceptable water soluble or water-dispersible carrier material in a vehicle; (b) introducing the medicament and vehicle into a reservoir for a nebulizer; (c) freezing the medicament and the vehicle in the reservoir and (d) lyophilizing. The method provides a solid state open matrix network of the medicament in the reservoir, ready to use simply by adding vehicle.

10 Alternatively, the medicament and carrier in vehicle may be lyophilized and then transferred into the reservoir.

In preferred embodiments of all of the above aspects, the medicament is formoterol or a salt thereof. A particularly preferred medicament is R,R-formoterol, and a particularly preferred salt is R,R-formoterol-L-tartrate. The pharmaceutically acceptable water soluble or water-dispersible carrier material is a protein, polypeptide or polysaccharide, preferably gelatin, alginate or dextran.

#### Brief Description of the Drawings

20 The invention may be best understood by reference to the detailed description of the preferred embodiments herein when read in conjunction with drawings in which:

25 Figure 1 depicts an unassembled perspective view of the components that make up a nebulizer device, showing the deposition of a matrix according to the principles of the present invention;

Figure 2 depicts a cross-sectional schematic representation of a two-chambered container having a matrix deposited therein in accordance with the principles of the present invention; and

5 Figure 3 depicts a sectional representation of a metered dose nebulizer, showing the operational positioning of the container of Figure 2.

#### Detailed Description of the Invention

The common feature that links all of the aspects of the invention is the use of a solid state open matrix network of a medicament to quickly generate a precisely controlled volume of an aqueous solution suitable for aerosol 10 administration. The precise measurement of very small amounts of solids is difficult and homogeneity becomes critical when small amounts of highly potent agents are to be dispensed. The invention provides a particular advantage in the manufacture of dosage forms for aerosol administration in that it enables the manufacturer to precisely meter a solution (prior to lyophilization) rather than 15 having to weigh or otherwise measure a powder. Additionally, the use of the solid phase matrix in the various embodiments of the invention allows an individual patient to make up a sterile aerosol solution accurately, immediately before use and without the involvement of a health care professional. Accuracy and sterility are both important considerations in inhalation therapy.

20 The invention employs a pharmaceutical dosage form which can be rapidly disintegrated by water. By "rapidly disintegrated" is meant that the solid state matrices are disintegrated in water within 15 seconds. Preferably the solid state matrix disintegrates (dissolves or disperses) within 10 seconds or less. The disintegration time is measured by a procedure analogous to the Disintegration 25 Test for Tablets, USP XXII, Dissolution <711>, p. 1578-1579 (1990). The procedure is as follows:

A glass or suitable plastic tube 80 to 100 mm long, with an internal diameter of about 28 mm and an external diameter of 30 to 31 mm, is fitted at the lower end, so as to form a basket, with a disc of rustproof wire gauze complying with the requirements for a No. 1.70 sieve. The basket is suspended 5 centrally in a glass or plastic cylinder having a flat base and an internal diameter of about 45 mm. The cylinder contains water 15 cm deep at a temperature between 36° and 38° C. The basket is raised and lowered repeatedly in such a manner that the complete up and down movement is repeated thirty times a minute. At the highest position the gauze just breaks the surface of the water and 10 at the lowest position the upper rim of the basket just remains clear of the water. Place the solid state matrix in the basket and raise and lower it. The solid state matrices are disintegrated when no particle remains above the gauze which would not readily pass through it. No such particle should remain after 15 seconds.

15 By the term "open matrix network" there is meant a network of water-soluble or water-dispersible carrier material having dispersed interstices. The open matrix network of carrier material is of generally low density. The density will generally be within the range of 10 to 200 mg/cc, and most commonly 30 to 60 mg/cc. The density of the solid state matrix is affected by the amount of 20 medicament or additive incorporated, and may on occasion fall outside the above mentioned preferred limits. The open matrix network, which is similar in structure to a solid, open-cell foam, enables the aqueous vehicle to enter the product through the interstices and permeate through the interior. Permeation by aqueous media exposes the carrier material of both the interior and exterior of 25 the product to the action of the aqueous medium, whereby the network of carrier material is rapidly disintegrated.

The carrier material used in the product of the invention may be any water-soluble or water-dispersible material that is pharmacologically acceptable or inert to the medicament and which is capable of forming a rapidly

disintegratable open matrix network. Use of a water-soluble material as the carrier results in the most rapid disintegration of the matrix when the product is placed in an aqueous medium. A particularly advantageous carrier may be formed from a protein such as gelatin, particularly partially hydrolyzed gelatin.

5 The hydrolyzed gelatin is preferably used at concentrations of about 1 to 6% weight/volume based on the volume of the initial solution, prior to lyophilization. Other carrier materials include polysaccharides such as hydrolyzed dextran, dextrin and alginates (e.g. sodium alginate) or mixtures of above mentioned carriers with each other or with other carrier materials such as

10 polyvinyl alcohol, polyvinylpyrrolidine or acacia. The solid state matrices of the present invention may incorporate ingredients in addition to the medicament, for example coloring agents, flavoring agents, preservatives (e.g. bacteriostatic agents), and the like.

The solid state matrices of the present invention are prepared by

15 subliming (lyophilizing) solvent (usually water) from a composition comprising the medicament and a solution of the carrier material in a solvent, the composition being in the solid state in a mold, which can be a reservoir for a nebulizer. Although the solvent is primarily water, it may contain a co-solvent such as t-butanol when necessary to improve the solubility of the medicament.

20 The composition may also contain a surfactant e.g. Tween 90 [polyoxyethylene (20) sorbitan-mono-oleate] to aid in the dispersion of the medicament.

The mold may be in the form of a tray having a series of cylindrical or other shape depressions in it, each of a size corresponding to the desired size of the solid state matrix. Alternatively, the size of the depression may be larger

25 than the desired size of the article and, after the contents have been freeze dried, the product can be cut into the desired size (for example thin wafers). In one embodiment the mold comprises an aluminum film containing one or more depressions. In another embodiment, the mold is a body (usually plastic) suitable for use as a reservoir for a nebulizer. The mold is cooled, a

predetermined amount of water containing the carrier material, the medicament and any other desired ingredient is introduced into the mold, frozen, and subjected to reduced pressure. The freeze dried products may then be removed from the mold and stored, protected from moisture, or the freeze dried products 5 may be left in the mold and the mold may be sealed with a moisture-impermeable, pealable overwrap. If the freeze drying has been carried out in a nebulizer reservoir, the reservoir can be sealed with a moisture-impermeable seal as discussed below. Alternatively, the matrices may be taken from a mold and placed in a reservoir, which is then sealed with the moisture impermeable 10 seal.

The following examples illustrate the preparation of the matrix:

#### EXAMPLE 1

A hydrolyzed gelatin solution is prepared by dissolving 30 g of gelatin in 1L of water and heating at 121° C at 1.03 bar for one hour. The solution is 15 allowed to cool to room temperature. One gram of R,R-formoterol-L-tartrate is dissolved in the solution. A mold in the form of an aluminum film containing 75 cylindrical depressions (each depression being about 0.5 cm diameter and 1 cm deep) is cooled to about - 192° C in liquid nitrogen contained in a stainless steel tray. One half milliliter of the mixture is introduced into each depression and 20 frozen. The mold is placed in a vacuum chamber at room temperature and a vacuum of 0.3 mm Hg is applied for 12 hours. The freeze dried matrices, each containing 0.5 mg of formoterol tartrate (about 10 to 20 unit doses), are covered with a pealable aluminum seal.

The amount of R,R-formoterol-L-tartrate dissolved in the hydrolyzed 25 gelatin solution can be varied to provide unit doses rather than multiple doses. When a unit dose (e.g. 50 µg) is desired, one would use 100mg/L rather than the 1g/L described. Reasonable limits for R,R-formoterol-L-tartrate are between 6 mg/L and 200 mg/L for preparing unit doses. The freeze dried matrices may be

sealed in a blister-pack type mold in which they were produced, as described above, or they may be placed in a nebulizer reservoir and sealed therein.

#### EXAMPLE 2

Twenty grams of acacia is placed in a dry 1L flask and about 10 mL of 5 absolute alcohol is added. The flask is shaken to wet the acacia powder, and 500 mL of distilled water is introduced and shaken to yield a homogeneous solution. Thirty grams of polyvinylpyrrolidine and 1 g of R,R-formoterol-L-tartrate are dispersed into the solution with the aid of ultrasonic vibration. The final volume is adjusted to 1L with distilled water and 1 mL of the composition is added to 10 each container (for multiple doses) or 20 to 50  $\mu$ L is added to each container (for a unit dose). The lyophilization is carried out as described above. The container is then sealed with a sealable seal.

#### EXAMPLE 3

A hydrolyzed gelatin solution is prepared as in example 1. One gram of 15 R,R-formoterol tartrate is dissolved in the solution. The final volume is adjusted to 1L with distilled water and 2 mL of the composition is added to a two-chamber container. The lyophilization is carried out as described above. The two-chamber vial is then sealed with a water impermeable seal.

The matrices prepared according to example 1 may be provided to the 20 user as a component of a kit. The other component of the kit is a container containing the appropriate amount of buffered saline, or other suitable aqueous vehicle, sufficient to dissolve a single matrix (wafer) and provide a sterile, homogenous solution of precisely controlled concentration. Thus, for example, a wafer may contain 20-50  $\mu$ g of R,R-formoterol tartrate, which is the range for 25 one unit dose for inhalation. In that case, the second container may contain 2 mL of saline. The second container containing the saline may be a sealed nebulizer reservoir. In use, the wafer would be transferred from its sealed blister pack into a nebulizer reservoir and combined with the saline components. The wafer

dissolves within seconds and provides the solution for a single inhalation session.

Alternatively, matrices may be prepared in accordance with example 2, wherein the container in which the solution is lyophilized is a reservoir for use in a nebulizer. The kit would then comprise the matrix in a sealed nebulizer reservoir as the first component and a container containing the appropriate amount of buffered saline, or other suitable aqueous vehicle, sufficient to dissolve the matrix as the other container. Similarly, the matrices may be prepared in accordance with example 1, placed in the nebulizer reservoir and sealed. In either case, addition of the saline to the reservoir provides a sterile, homogenous solution. The second container may contain 5-10 mL of saline.

Nebulizers and reservoirs suitable for the practice of this invention are commercially available from PARI Respiratory Equipment, Midlothian, VA. A schematic diagram of such a device is shown in Fig 1, in which 2 is the inspiratory valve cap, 4 is the nebulizing chamber, 6 is the reservoir, 8 is the source of gas (air) and 10 is the mouthpiece. The reservoir is sealed at the top, at the air inlet 8 and at the mouthpiece orifice 9 with sealable seals 12, 14 and 18, and contains the lyophilized matrix 16. In use, the patient would remove the seals 12, 14 and 18, add the saline from the second container (not shown) and insert the chamber 4 with valve 2 attached into the reservoir 6.

In another embodiment, the matrix is created in a two-chambered container, as described in example 3. The container is a modification of the container described in US patents 3,464,414; 4,331,233; 4,274,543; 4,267,925; 4,258,845; 4,194,640 and 4,089,432; the disclosures of which are incorporated herein by reference. The container 20 is shown in Fig. 2. The container is manufactured in an hourglass shape and a deformable elastomeric seal 22 is positioned in the neck. The matrix 16 is deposited on one side of the elastomeric seal and the aqueous vehicle (usually saline) 24 is placed on the opposite side.

The container is closed at one end with a closure 26 having the structure described in the above patents. The closure is provided with a water and microorganism-tight seal such that the stopper 36 may be displaced and the elastomeric seal 22 can thereby be urged out of contact with the walls of the neck

5       30 of container 20, allowing the saline to enter the second chamber 32 in which the matrix resides. The chamber 32 containing the matrix is itself provided with a valve 34. The valve is of the type commonly employed in metered dose dispensers such as that sold by Aerogen, Inc., Santa Clara, CA and described in US patent 5,586,550, the disclosure of which is incorporated herein by reference.

10       The use of the dual chamber vial in an Aerogen™ metered dose nebulizer is shown in Fig 3. In operation, the stopper would be depressed by the user as described above, to generate the aqueous solution of medicament, and the dual chamber vial 20 would be inserted into the device 40, in which the oscillator described in US patent 5,586,550 is 42. Also shown are the batteries 44, the 15       circuit board 46, the acoustic inhalation detector 48 and the mouthpiece 50.

Although this invention is susceptible to embodiment in many different forms, preferred embodiments of the invention have been shown. It should be understood, however, that the present disclosure is to be considered as an exemplification of the principles of this invention and is not intended to limit the 20       invention to the embodiments illustrated.

## CLAIMS

- 1 1. A pharmaceutical kit for aerosol administration comprising: (a) a solid  
2 state open matrix network of a medicament and a pharmaceutically acceptable  
3 water soluble or water-dispersible carrier material contained within a first  
4 substantially water-impermeable container; and (b) a sufficient quantity of an  
5 aqueous vehicle to dissolve said matrix network within fifteen seconds contained  
6 within a second substantially water-impermeable container.
  
- 1 2. A kit according to claim 1 wherein said first container containing said  
2 solid state network and said second container containing said vehicle are  
3 separate.
  
- 1 3. A kit according to claim 1 wherein said first container containing said  
2 solid state network and said second container containing said vehicle are  
3 chambers within a single housing.
  
- 1 4. A kit according to claim 1 wherein said medicament is formoterol  
2 tartrate.
  
- 1 5. A kit according to claim 1 wherein said medicament is R,R-formoterol-  
2 L-tartrate.
  
- 1 6. A kit according to claim 1 wherein said pharmaceutically acceptable  
2 water soluble or water-dispersible carrier material is a protein, polypeptide or  
3 polysaccharide.
  
- 1 7. A kit according to claim 1 wherein said solid state network is a unit dose  
2 of said medicament and said quantity of aqueous vehicle is a quantity needed to  
3 deliver one unit dose by nebulization.

1       8.     A kit according to claim 1 wherein said solid state network contains a  
2       plurality of unit doses of said medicament and said quantity of aqueous vehicle is  
3       a quantity needed to deliver said plurality of unit doses by nebulization.

1       9.     A kit according to claim 8 additionally comprising a metered dose  
2       nebulizer.

1       10.    A pharmaceutical kit for aerosol administration comprising a solid state  
2       open matrix network of a medicament and a pharmaceutically acceptable water  
3       soluble or water-dispersible carrier material contained within a nebulizer  
4       reservoir and enclosed by a substantially water-impermeable seal, said seal being  
5       penetrable by a patient prior to use of said nebulizer.

1       11.    A kit according to claim 10 wherein said solid state network contains a  
2       plurality of unit doses of said medicament.

1       12.    A kit according to claim 10 wherein said medicament is formoterol  
2       tartrate.

1       13.    A kit according to claim 10 wherein said medicament is R,R-formoterol-  
2       L-tartrate.

1       14.    A method for preparing an aerosol formulation comprising: (a) providing  
2       a solid state open matrix network of a medicament and a pharmaceutically  
3       acceptable water soluble or water-dispersible carrier material; and (b) combining  
4       said matrix network with a sufficient quantity of an aqueous vehicle to dissolve  
5       said matrix network within fifteen seconds.

1       15.    A method according to claim 14 wherein said open matrix network is a  
2       network of formoterol tartrate and a pharmaceutically acceptable water soluble  
3       or water-dispersible carrier material.

1       16.    A method according to claim 14 wherein said open matrix network is a  
2       network of R,R-formoterol-L-tartrate and a pharmaceutically acceptable water  
3       soluble or water-dispersible carrier material.

1       17.    A method for administering a water-sensitive medicament as a nebulized  
2       aqueous aerosol comprising: (a) dissolving a solid state open matrix network of a  
3       medicament and a pharmaceutically acceptable water soluble or water-  
4       dispersible carrier material in a sufficient quantity of an aqueous vehicle to  
5       dissolve said matrix network within fifteen seconds to provide an aqueous  
6       solution; and (b) nebulizing said aqueous solution.

1       18.    A method according to claim 17 wherein said medicament is formoterol  
2       tartrate.

1       19.    A method according to claim 17 wherein said medicament is R,R-  
2       formoterol-L-tartrate.


1       20.    A method for providing a water-sensitive medicament for inhalation  
2       comprising: (a) dissolving or suspending a water-sensitive medicament and a  
3       pharmaceutically acceptable water soluble or water-dispersible carrier material in

4 a vehicle; (b) introducing said medicament and vehicle into a reservoir for a  
5 nebulizer; (c) freezing said medicament and vehicle in said reservoir and (d)  
6 lyophilizing said medicament and vehicle in said reservoir to provide a solid  
7 state open matrix network of said medicament and carrier in said reservoir.

1 21. A method according to claim 20 wherein said medicament is formoterol  
2 tartrate.


1 22. A method according to claim 20 wherein said medicament is R,R-  
2 formoterol-L-tartrate.

1/3




**FIG. 1**

2/3

**FIG. 2**

3/3

**FIG. 3**

## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/US 98/21115A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K9/72 865025/08 A61K31/135

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K B65D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 366 835 A (WYETH JOHN & BROTHER LTD) 5 May 1978 see page 2, line 3-8 see page 2, line 23-35 see page 4, line 14-25 see page 4, line 33 - page 5, line 2 see page 6, line 11-20 see page 6, line 37 - page 7, line 1 see claims 1,2 ---	1,14,17, 20
A	EP 0 651 997 A (YAMANOUCHI PHARMA CO LTD) 10 May 1995 see page 8, line 22-24 see example 12 ---	1,4,5 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## • Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"S" document member of the same patent family

Date of the actual completion of the International search

11 February 1999

Date of mailing of the International search report

17/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax. (+31-70) 340-3016

Authorized officer

La Gaetana, R

## INTERNATIONAL SEARCH REPORT

Inte [REDACTED] Application No  
PCT/US 98/21115

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 089 432 A (CRANKSHAW GARY K ET AL) 16 May 1978 cited in the application see column 1, line 5-21 see figures ----	1,3,10, 17
A	WO 97 35882 A (ORTHO PHARMA CORP) 2 October 1997 see page 3, line 5 - page 4, line 6 see page 4, line 26 - page 5, line 11 see page 7, line 13-25 see page 8, line 11-14 see example 1 see claims 5,6,8 ----	1,2,6,7, 14,17,20
A	US 3 898 338 A (MARTIN TELLIS ALEXANDER ET AL) 5 August 1975 see column 8, line 16-41 ----	1,2,7, 14,17

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Inte... Application No

PCT/US 98/21115

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
FR 2366835	A 05-05-1978	GB 1548022 A		04-07-1979
		AU 513845 B		08-01-1981
		AU 2882577 A		22-03-1979
		CA 1097233 A		10-03-1981
		CH 633717 A		31-12-1982
		CY 1129 A		19-02-1982
		DE 2744493 A		13-04-1978
		HK 58081 A		04-12-1981
		IE 45770 B		17-11-1982
		JP 1446344 C		30-06-1988
		JP 53044619 A		21-04-1978
		JP 62050445 B		24-10-1987
		KE 3171 A		18-12-1981
		LU 78259 A		09-06-1978
		NL 7710876 A, B,		10-04-1978
		US 4305502 A		15-12-1981
		BE 859291 A		30-03-1978
		CA 1083042 A		05-08-1980
		JP 1509556 C		26-07-1989
		JP 61118314 A		05-06-1986
		JP 63052008 B		17-10-1988
		US 4371516 A		01-02-1983
		ZA 7705465 A		25-04-1979
EP 0651997	A 10-05-1995	AU 3095992 A		28-07-1993
		DE 69227467 D		03-12-1998
		FI 943042 A		23-06-1994
		JP 2807346 B		08-10-1998
		NO 942403 A		24-08-1994
		US 5466464 A		14-11-1995
		AT 172637 T		15-11-1998
		CA 2126669 A		08-07-1993
		HU 75455 A		28-05-1997
		WO 9312769 A		08-07-1993
		NZ 246091 A		28-08-1995
US 4089432	A 16-05-1978	AU 508032 B		06-03-1980
		AU 3584478 A		08-11-1979
		BE 866440 A		27-10-1978
		BR 7802763 A		26-12-1978
		CA 1103209 A		16-06-1981
		DE 2817618 A		09-11-1978
		FR 2389550 A		01-12-1978
		GB 1604902 A		16-12-1981
		GR 64434 A		21-03-1980
		JP 54001181 A		06-01-1979
		US 4194640 A		25-03-1980
		ZA 7802462 A		25-04-1979
WO 9735882	A 02-10-1997	AU 2322097 A		17-10-1997
US 3898338	A 05-08-1975	US 3809697 A		07-05-1974
		AU 463873 B		07-08-1975
		AU 4744372 A		11-04-1974
		BE 789811 A		06-04-1973
		CA 1003838 A		18-01-1977
		DE 2249054 A		26-04-1973
		FR 2161910 A		13-07-1973

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Intee [REDACTED] Application No

PCT/US 98/21115

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3898338	A	GB 1370980 A	23-10-1974
		JP 48044273 A	26-06-1973
		NL 7213558 A	10-04-1973
		SE 386175 B	02-08-1976
		ZA 7207046 A	27-06-1973